Lv5
1240 积分 2023-05-08 加入
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models
2个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
2个月前
已完结
Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
3个月前
已完结
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
3个月前
已完结
ORM-5029: Discovery of an antibody drug conjugate with first-in-class molecular glue degrader warhead for treatment of HER2-positive breast cancer
3个月前
已完结
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
6个月前
已完结
Mutations in the human Delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis
8个月前
已完结
Emerging antibody-based therapies for the treatment of acute myeloid leukemia
9个月前
已完结
Organoids — Preclinical Models of Human Disease
11个月前
已完结
Preclinical models for drug discovery for metastatic disease
11个月前
已完结
皖公网安备34019202002308
